SWEDISH ORPHAN Profile

Performance

1414
   

Odds of Distress

Check how we calculate scores
Equity ratings for SWEDISH ORPHAN BIOVITRUM AB are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 17, 2019 and ending today September 15, 2019. Click here to learn more.

SWEDISH ORPHAN BIOVI Risk Profiles

SWEDISH ORPHAN Key Fundamentals

SWEDISH ORPHAN Against Markets

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on BATS Exchange in USA. more
NameSWEDISH ORPHAN BIOVITRUM AB
CEOGeoffrey McDonoughView All
Macroaxis Advice
InstrumentUSA OTC Stock View All
Business AddressTomtebodavAgen 23A
ExchangeBATS Exchange
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
BenchmarkDOW
Websitewww.sobi.com
Phone46 86 97 20 00
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018

SWEDISH ORPHAN Corporate Directors

Hans Wigzell Independent Director
Lennart Johansson Director
Annette Clancy Independent Director
Check also Trending Equities. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com